Blood groups, components and transfusion reactions
Compatibility is component specific
ABO, Rh and other antigen systems influence compatibility, but compatibility is not determined by one label alone. Forward typing, reverse typing, antibody screening and the actual crossmatch answer different questions. A person with a rare phenotype can have an antibody relevant even to group O red cells. Partial and weak antigen expression require genotype-appropriate interpretation rather than a rule that all weak-D findings share the same management. A historical antibody can remain clinically important after its circulating concentration becomes difficult to detect.
Select the component and modification
Red cells, platelets, plasma and fibrinogen-containing products address different deficits. A normal or abnormal INR alone does not specify a need for every plasma transfusion. Bleeding, procedure risk, cause, physiological stability and an appropriate framework affect the decision. Irradiation reduces the risk from viable donor lymphocytes in relevant cellular components; leukoreduction has a different purpose and does not replace irradiation when it is indicated. Neither modification makes a component universally free of infectious or immunological risk. Donor relation and relevant therapies can change the need for a modification.
Investigate the reaction, not just the label
New symptoms during transfusion require prompt assessment and the appropriate safety response. Acute hemolysis, bacterial contamination, allergic reactions, circulatory overload and lung injury can overlap in their early presentation. An acute ABO-incompatible reaction can activate complement, whereas a delayed anamnestic antibody can lead to donor-cell clearance after an initially compatible-looking assessment. TRALI involves a noncardiogenic pulmonary injury process and is not necessarily antibody mediated in every case. TACO involves circulatory overload, but biomarkers have limitations, particularly with preexisting renal or cardiac disease. A response to a diuretic contributes information without independently proving the whole diagnosis.
Interpret response and ongoing needs
Platelet response can be impaired by immune or nonimmune mechanisms. A low increment after one transfusion is not proof of an HLA antibody. Timing, dose, body size, fever, bleeding, splenic distribution and repeated observations matter. Massive transfusion can produce electrolyte, temperature and coagulation problems requiring coordinated reassessment. Citrate exposure can lower ionized calcium, while stored-cell changes affect several biochemical properties. A component count or numerical transfusion trigger is not a complete individualized prescription. Document the indication, monitor the response and communicate important antibody or reaction history so that subsequent care does not repeat an avoidable error.